Market Overview

BWS Financial Initiates Verso Corp At Buy, Sees Opportunity For Upside Following Bankruptcy

BWS Financial Initiates Verso Corp At Buy, Sees Opportunity For Upside Following Bankruptcy

BWS Financial has started coverage of Verso Corporation (NYSE: VRS) with a Buy rating and price target of $25, implying a potential upside of 117 percent over Tuesday's close of $11.53.

Memphis, Tennessee-based Verso is a producer of coated paper, which is used in magazines, catalogs and high-end advertising. The initiation comes after the company successfully emerged from bankruptcy in mid-July.

Verso's restructuring reduced the company's debt by $2.4 billion and includes $595 million in exit financing to support ongoing operations and capital investment. BWS said the restructuring should allow Verso to be profitable from day one as a new entity.

Related Link: Fibria Celulose Downgraded At Morgan Stanley On Brazilian Currency Concerns

In a research note, BWS Financial said Verso continues to dominate the coated paper industry in North America with 50 percent market share, which should boost profitability in the remainder of 2016 and into 2017.

"A profitable business with positive free cash flow should enable VRS to invest in the business to grow organically," analyst Hamed Khorsand wrote in a note dated July 20.

For 2016, Khorsand expects EPS of $2.04 on revenue of $1.36 billion.

At time of writing, shares of Verso were seen up 1.46 percent at $11.80.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for VRS

Aug 2019MaintainsNeutral
Apr 2019DowngradesBuyNeutral
Sep 2018MaintainsBuyBuy

View More Analyst Ratings for VRS
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Price Target Commodities Initiation Markets Analyst Ratings Movers Best of Benzinga


Related Articles (VRS)

View Comments and Join the Discussion!

Can Keytruda Deliver Earnings Growth For Merck?

Technical Alert - Boeing Rally Off Q2 Report Falls Shy Of Yearly High